While several COVID-19 vaccines have been in use, more effective and durable vaccines are needed to combat the ongoing COVID-19 pandemic. Here, we report highly immunogenic self-assembling SARS-CoV-2 ...

Please provide your email address to receive an email when new articles are posted on . Among patients with low baseline HBsAg, 39% achieved HBsAg loss with tobevibart/elebsiran, which rose to 46% ...

The coexistence of HBsAg and anti-HBs has been reported in some chronic hepatitis B patients; however, the long-term outcomes of this serological profile have not been elucidated. We aimed to evaluate ...

Patients with chronic hepatitis B virus (HBV) infection in the immune-tolerant phase may still experience hepatic inflammation and disease progression, and could benefit from early antiviral treatment ...

Please provide your email address to receive an email when new articles are posted on . HBV-infected children treated with combination PEG-INF a-2b/nucleos(t)ide analogues achieved higher HBsAg loss ...

Professor of Medicine and Chief, Division of Hepatology, Center for Liver Disease, University of Miami School of Medicine, Miami, Florida Antiviral studies generally used intermediate markers of ...

Panel A shows the structure of HDV, which shares the hepatitis B surface antigen (HBsAg) envelope with hepatitis B virus. The virion contains a single-stranded, circular RNA genome of approximately ...

Hepatitis B virus is often silently undiagnosed, with only 10.5% of all people estimated to be living with Hepatitis B aware of their condition. Abbott has launched the HBsAg Next Qualitative Assay ...